Table 1. Comparisons of clinical variables and blood biomarkers between patients with normal SVR at 6 months (SVR-), those with abnormal SVR only at 6 months (SVR+) and those with abnormal SVR both at baseline and 6 months (SVR++).
| Baseline variables | 6-month variables | |||||||
|---|---|---|---|---|---|---|---|---|
| SVR- (n = 90) | SVR+ (n = 10) | SVR++ (n = 21) | P value | SVR- (n = 90) | SVR+ (n = 10) | SVR++ (n = 21) | P value | |
| Age (years) | 56 (49–61) | 56 (47–63) | 58 (49–72) | 0.54 | _____ | _____ | _____ | _____ |
| Female gender | 13 (14%) | 2 (20%) | 3 (14%) | 0.91 | _____ | _____ | _____ | _____ |
| History of hypertension | 25 (28%) | 3 (30%) | 11 (52%) | 0.10 | _____ | _____ | _____ | _____ |
| Body mass index (kg.m-2) | 24 (22–28) | 26 (24–28) | 25 (23–28) | 0.54 | 24 (22–27) | 26.9 (24–28) | 25 (24–28) | 0.15 |
| ACEI treatment | 77 (85%) | 8 (80%) | 18 (86%) | 0.91 | 78 (87%) | 10 (100%) | 16 (76%) | 0.22 |
| Beta-blocker treatment | 73 (81%) | 9 (90%) | 18 (86%) | 0.85 | 75 (83%) | 10 (100%) | 16 (76%) | 0.31 |
| Peak Creatine Kinase-MB (U.L-1) | 2513 (1052–4000) | 3647 (1374–4678) | 2209 (1263–2984) | 0.40 | _____ | _____ | _____ | _____ |
| Ln (peak Troponin (μg.L-1)) | 4.6 (4.3–6.3) | 5.3 (4.5–7.9) | 4.6 (4.1–5.2) | 0.58 | _____ | _____ | _____ | _____ |
| eGFR (mL.min-1 and per 1.73 m-2 of BSA) | 83.0 (72–94) | 77.0 (70–83) | 73.0 (65–82) | 0.10 | _____ | _____ | _____ | _____ |
| C-Reactive Protein (mg.L-1) | 12.7 (5.5–22.8) | 21.2 (13.7–52.2) | 12.9 (10.2–26.4) | 0.25 | 1.1 (0.6–2.1) | 2.0 (0.6–2.2) | 1.1 (0.6–2.9) | 0.43 |
| Brain Natriuretic Peptide (pg.mL-1) | 157 (82–266) | 177 (130–300) | 113 (62–205) | 0.19 | 52 (25–119) | 52 (23–77) | 63 (25–129) | 0.79 |
| NGAL (ng.mL-1) | 70 (59–87) | 84 (61–107) | 75 (65–107) | 0.14 | 64 (54–84) | 88 (57–115) | 79 (73–93)* | 0.014 |
| Renin (pg.mL-1) | 14.4 (6.8–28.2) | 18.9 (5.4–201.1) | 20.6 (9.0–80.0) | 0.25 | 26.9 (12.6–65.9) | 40.9 (13.8–128.0) | 33.6 (10.9–91.8) | 0.71 |
| Aldosterone (pg.mL-1) | 22.8 (15.6–31.0) | 26.3 (20.5–72.4) | 23.1 (20.1–40.0) | 0.29 | 58.3 (37.6–97.5) | 67.5 (38.9–196.9) | 64.2 (41.7–115.9) | 0.41 |
| Galectin-3 (ng.mL-1) | 11.7 (9.8–13.5) | 14.4 (12.3–16.7)* | 13.0 (11.7–19.4)* | 0.003 | 11.9 (10.2–13.2) | 12.3 (10.9–15.4) | 12.1 (10.8–16.5) | 0.29 |
ACEI, Angiotensin Converting Enzyme Inhibitors; BSA: body surface area; eGFR, estimated glomerular filtration rate; NGAL, Neutrophil Gelatinase-Associated Lipocalin.
*: p<0.05 for comparisons of SVR+ or SVR++ vs. SVR-, and
†: p<0.05 for comparisons of SVR++ vs. SVR+ at the same time point (baseline or 6 months).